Nuclear Medicine Market Size, Share and Growth Outlook 2026: By Product Type, By Application, By End-Use, Companies to 2034
The global Nuclear Medicine Market size is forecast to increase from $18.52 Billion in 2026 to $42.07 Billion in 2034 at a CAGR of 10.8% between 2026 and 2034.
The Nuclear Medicine market report provides detailed analysis and outlook of Nuclear Medicine segments including By Product Type (Diagnostics, SPECT Radiopharmaceuticals, PET Radiopharmaceuticals, Therapeutics, Alpha Emitters, Beta Emitters, Brachytherapy Isotopes ), By Application (Oncology, Cardiology, Neurology, Urology, Thyroid and Endocrine Disorders, Other Applications ), By End-Use (Hospitals, Diagnostic and Imaging Centers) across global and regional markets. Further, analysis and outlook across 21 countries in North America, Europe, Asia Pacific, Middle East, Africa, and South America are provided in the study.
Nuclear Medicine Industry Overview
Precision Diagnostics and Theranostics Are Accelerating Nuclear Medicine Adoption
The nuclear medicine industry is undergoing rapid transformation as healthcare providers increasingly adopt molecular imaging and radiopharmaceutical-based therapies to support precision medicine strategies. Nuclear medicine plays a critical role in oncology, cardiology, neurology, and rare disease management by enabling visualization of biological processes at the molecular level. The industry is experiencing strong momentum from the expansion of theranostics, which combines targeted diagnostic imaging with corresponding therapeutic interventions. Growing demand for personalized treatment planning, earlier disease detection, and image-guided therapy is driving investment across radiopharmaceutical development, isotope production infrastructure, imaging technologies, and clinical workforce training. As precision healthcare continues to advance, nuclear medicine is becoming an increasingly integrated component of modern diagnostic and therapeutic pathways.
Radiopharmaceutical Innovation Is Expanding Clinical Applications
A major industry trend is the expansion of approved radiopharmaceutical products and the strengthening of manufacturing capabilities required to support clinical adoption. RadioMedix received FDA approval for its generic Gallium Ga-68 Gozetotide radiodiagnostic agent used in prostate cancer imaging, further expanding access to molecular diagnostic tools that support targeted oncology care. The approval followed a successful inspection of the company’s SPICA Center radiopharmaceutical manufacturing facility without regulatory findings, highlighting the industry's emphasis on quality-controlled production environments. Growing utilization of prostate-specific membrane antigen imaging and other targeted radiotracers is reinforcing the importance of reliable radiopharmaceutical manufacturing infrastructure capable of supporting expanding clinical demand for advanced molecular imaging procedures.
Isotope Supply Expansion and Workforce Development Strengthen Industry Foundations
The long-term growth of nuclear medicine increasingly depends on robust isotope supply chains and specialized clinical expertise. TMC Group expanded production capacity at its Canadian isotope facility through the commissioning of new production lines dedicated to high-purity enriched stable isotopes such as Yb-176 and Gd-160. This expansion supports research, development, and commercialization activities associated with next-generation radiotheranostic agents. At the same time, the Society of Nuclear Medicine and Molecular Imaging Annual Meeting brought together nearly 8,000 participants and highlighted advancements across theranostics, AI-assisted quantitative imaging, and technologist training initiatives. Industry stakeholders are increasingly prioritizing workforce certification programs and therapy-focused clinical education to support the growing complexity of nuclear medicine procedures. These developments illustrate a broader industry effort to strengthen the infrastructure, talent base, and supply chain capabilities required to support the expanding role of precision nuclear medicine in healthcare delivery.
Nuclear Medicine Market Trends, Growth Drivers, Competitive Landscape, and Future Opportunities
The global Nuclear Medicine market is witnessing increasing investments in innovation, product development, digital transformation, artificial intelligence integration, healthcare infrastructure expansion, and strategic partnerships across developed and emerging economies. Key Companies in the industry include- GE Healthcare, Siemens Healthineers AG, Novartis AG, Curium Pharmaceuticals, Lantheus Holdings, Inc., Cardinal Health, Inc., Bracco Imaging S.p.A., Eckert & Ziegler Group, Jubilant DraxImage Inc., Mallinckrodt plc. The Nuclear Medicine market is expected to remain one of the most closely watched segments in the global healthcare industry, with companies focusing on niche market segments. As healthcare systems across the US, Europe, Asia-Pacific, Latin America, and Middle East & Africa continue to prioritize efficiency, access, and innovation, the Nuclear Medicine industry outlook remains shaped by rising healthcare expenditure, demographic change, digital transformation, and product innovation.
The report provides detailed market analysis including-
Leading companies in Nuclear Medicine industry include- GE Healthcare, Siemens Healthineers AG, Novartis AG, Curium Pharmaceuticals, Lantheus Holdings, Inc., Cardinal Health, Inc., Bracco Imaging S.p.A., Eckert & Ziegler Group, Jubilant DraxImage Inc., Mallinckrodt plc. The Nuclear Medicine market remains moderately to highly fragmented, with competition expected to intensify as companies accelerate investments in innovation, geographic expansion, strategic partnerships, and portfolio diversification through 2034. In developed markets such as the United States, Germany, France, the United Kingdom, and Canada, competition is increasingly centered on innovation, reimbursement positioning, and value-based healthcare solutions. Meanwhile, emerging markets including China, India, Brazil, and countries across the Middle East and Africa continue to present significant opportunities for expansion due to rising healthcare expenditure, growing patient populations, and increasing access to healthcare services.
What to expect in US Nuclear Medicine Markets in 2026 and beyond- Market Size, Share, Growth Rate, and Forecast to 2034
The US healthcare expenditure is forecast to reach $8.2 Trillion in 2034 from $5.5 Trillion in 2026 based on the National Health Expenditure Accounts (NHEA) data. With an aging population, rising chronic disease burden, and increasing migration toward minimally invasive and outpatient care, the Nuclear Medicine market remains one of the strongest-performing segments in the country.
The US Nuclear Medicine Companies are opting new business models, optimized pricing models, industry partnerships, and AI-enabled back end transformations to enhance efficiency and cost management. The US Nuclear Medicine market faces successive waves of challenging trends, with strong opportunities across select segments. The CMS plan to implement Medicaid from 2027 is driving states to build eligibility verification systems throughout 2026. Looking ahead to 2034, we anticipate stronger results underpinned by opportunities exist across Nuclear Medicine industry. On the medical device front, over 7,000 device manufacturers continue to gain from increasing demand from demand for implantable devices, surgical instruments, monitoring equipment, and diagnostic systems.
Canada- Proximity to the US and healthcare similarities to EU5 countries fuel sales of Canadian Nuclear Medicine markets
Canada's strong Nuclear Medicine sales performance is underpinned by an aging population and a well-developed healthcare infrastructure. Steady growth in new brand spending in rural and urban locations fuel the long-term prospects of small and medium-sized enterprises across medical, diagnostic, and therapeutic devices. The Canadian Nuclear Medicine market presents significant opportunities for U.S. exporters of medical devices, with the U.S. being Canada’s largest trading partner for this sector. Potential advantages including specialized materials, advanced manufacturing techniques, and digital technologies support the launch of new products in the country.
Germany Nuclear Medicine Trends and Perspectives to 2034- Financial sustainability, hospital restructuring, demographic pressures, and digitization of care delivery continue to shape the German healthcare industry.
Germany continues to remain the largest Nuclear Medicine market in Europe, driven by over €600 Billion healthcare expenditure, €12 Billion medical device R&D expenditure, statutory health insurance system covering 90% German population, nationwide rollout of the electronic patient record (ePA), and large-volume of Nuclear Medicine population. In particular, Research and development in Germany fuels the commercialization of cutting-edge technologies. Companies across the Germany Nuclear Medicine industry value chain are focusing on both domestic markets and exports. The country is also driving digital adoption with the Hospital Future Act driving hospitals to upgrade their information systems by 2027. Over the forecast period, aging population, rising healthcare costs, and increasing procedural volumes drive the Nuclear Medicine market outlook.
France Market Size, Growth Rate, and Forecast Analysis to 2034- Universal healthcare system, high public healthcare expenditure, and strong government support Nuclear Medicine sales through 2034
France Nuclear Medicine companies are emphasizing on opportunities for rapid, at-scale innovation to boost profitability over the long-term. The country’s National Health Insurance spending target (ONDAM) estimates 3.7% growth in the country’s healthcare expenditure. Over the forecast period, expenditure control measures, chronic disease management initiatives, workforce reforms, and efforts to improve system efficiency drive the long-term prospects.
The biggest 2026 policy frame is the PLFSS 2026. The law sets the Maladie branch spending target at €271.4 billion for 2026 and fixes the ONDAM at €117.5 billion for city care, €112.8 billion for health establishments, and €18.3 billion for elderly-care establishments and services. France’s market is also being pulled by demographics. INSEE estimates that on 1 January 2026 France had 69.1 million inhabitants, with 22% aged 65 or over. INSEE also reported that 2025 births were 645,000 and deaths were 651,000, producing a negative natural balance of about 6,000 for the first time since the end of the Second World War.
UK Nuclear Medicine Market Size, Share, and Growth Projections to 2034- Rapid growth driven by new and existing brands across the industry value chain
Small high-need consumer segments remain key priority of Nuclear Medicine distributors in the UK industry. Continuous launch of new products coupled with high expenditures support the market outlook. The UK Government financing remains the dominant funding source at 81.3% of total healthcare expenditure, or ?280 billion in 2025. According to the ONS, total healthcare spending grew 7.7% nominally and 3.9% in real terms from 2024 to 2025. Similarly, out-of-pocket spending was ?49 billion (14.1%) and voluntary health insurance was ?9.5 billion (2.8%). The market is driven by rapid digital adoption with NHS England’s plan to give more than 500,000 staff access to new AI tools.
China Nuclear Medicine Market Growth Drivers, Revenue Trends, and Forecast- Medical insurance coverage is rapidly expanding over the past few years
China Nuclear Medicine market is undergoing a structural shift from hospital-centric care toward a more integrated system emphasizing primary care, outpatient services, and long-term care. Chinese local players are emerging as a strong pillar of Nuclear Medicine industry, offering opportunities for both competition and partnership. Over the forecast period, new and innovative product launches remain key elements driving market outlook. China's healthcare industry is increasingly centered on expanding healthcare capacity, improving access to advanced treatments, and reducing dependence on imported technologies.
The National Healthcare Security Administration reported that by end-2024, China’s basic medical insurance covered 1.32662 billion people and the coverage rate was 95%. Regional disparities in consumer spending trends continue to become more pronounced in the Chinese Nuclear Medicine industry. Over the forecast period, demand will keep shifting toward geriatrics, chronic disease management, rehabilitation, long-term care, and outpatient care, while pricing pressure will remain intense in drugs and consumables because reimbursement.
India Nuclear Medicine Market Landscape: Current Size and Long-Term Growth Outlook - Increased pricing pressures in US market is encouraging domestic vendors to expand across India
Indian Nuclear Medicine market is witnessing the rapid emergence of an ecosystem that brings together diverse companies across the industry value chain. Further, large-scale healthcare public and private investments and a steady growth in chronic conditions is driving sales of pharmaceuticals and medical devices. Further, non-retail channel is experiencing volume decrease and patients are migrating to the retail. Indian medical device firms are also combining precision engineering with lower labor costs to make world-class diagnostics, robotics, and critical care devices.
Brazil Nuclear Medicine market remains price-driven, with products domestically manufactured and accessibility offering potential opportunities
Healthcare expenditure in Brazil exceeds 10% of GDP, with the country among the highest healthcare spenders in Latin America. ANS reported 53.2 million medical-plan beneficiaries in December 2025, while IBGE projects a steady rise in older-age cohorts, with people aged 60+ already representing about 23% of the population. The price sensitive market access is broad through the public system, private coverage adds a sizeable premium layer, and reimbursement, procurement, and hospital efficiency remain key buying drivers.
Middle East and Africa Nuclear Medicine Industry Trends and Perspectives to 2034
According to the World Bank, the Middle East and North Africa population exceeds 500 million, while Sub-Saharan Africa's population exceeds 1.2 billion, making the broader MEA region one of the fastest-growing healthcare demand centers globally. The GCC countries including Saudi Arabia, United Arab Emirates, Qatar, and Kuwait continue to account for a disproportionately large share of regional healthcare spending. Government-led programs such as Saudi Arabia's Vision 2030 are accelerating investments in hospital infrastructure, private-sector participation, medical technology adoption, and healthcare digitalization. On the other hand, South Africa, Egypt, Nigeria, and Kenya remain key healthcare markets due to their large populations, expanding private healthcare sectors, and growing investments in healthcare delivery systems.
Nuclear Medicine Market Segmentation
By Product Type
Diagnostics
SPECT Radiopharmaceuticals
PET Radiopharmaceuticals
Therapeutics
Alpha Emitters
Beta Emitters
Brachytherapy Isotopes
By Application
Oncology
Cardiology
Neurology
Urology
Thyroid and Endocrine Disorders
Other Applications
By End-Use
Hospitals
Diagnostic and Imaging Centers
Leading Companies in Nuclear Medicine Industry (2026)
GE Healthcare
Siemens Healthineers AG
Novartis AG
Curium Pharmaceuticals
Lantheus Holdings, Inc.
Cardinal Health, Inc.
Bracco Imaging S.p.A.
Eckert & Ziegler Group
Jubilant DraxImage Inc.
Mallinckrodt plc
Countries Included
The Nuclear Medicine market report provides detailed analysis and outlook of Nuclear Medicine segments including By Product Type (Diagnostics, SPECT Radiopharmaceuticals, PET Radiopharmaceuticals, Therapeutics, Alpha Emitters, Beta Emitters, Brachytherapy Isotopes ), By Application (Oncology, Cardiology, Neurology, Urology, Thyroid and Endocrine Disorders, Other Applications ), By End-Use (Hospitals, Diagnostic and Imaging Centers) across global and regional markets. Further, analysis and outlook across 21 countries in North America, Europe, Asia Pacific, Middle East, Africa, and South America are provided in the study.
Nuclear Medicine Industry Overview
Precision Diagnostics and Theranostics Are Accelerating Nuclear Medicine Adoption
The nuclear medicine industry is undergoing rapid transformation as healthcare providers increasingly adopt molecular imaging and radiopharmaceutical-based therapies to support precision medicine strategies. Nuclear medicine plays a critical role in oncology, cardiology, neurology, and rare disease management by enabling visualization of biological processes at the molecular level. The industry is experiencing strong momentum from the expansion of theranostics, which combines targeted diagnostic imaging with corresponding therapeutic interventions. Growing demand for personalized treatment planning, earlier disease detection, and image-guided therapy is driving investment across radiopharmaceutical development, isotope production infrastructure, imaging technologies, and clinical workforce training. As precision healthcare continues to advance, nuclear medicine is becoming an increasingly integrated component of modern diagnostic and therapeutic pathways.
Radiopharmaceutical Innovation Is Expanding Clinical Applications
A major industry trend is the expansion of approved radiopharmaceutical products and the strengthening of manufacturing capabilities required to support clinical adoption. RadioMedix received FDA approval for its generic Gallium Ga-68 Gozetotide radiodiagnostic agent used in prostate cancer imaging, further expanding access to molecular diagnostic tools that support targeted oncology care. The approval followed a successful inspection of the company’s SPICA Center radiopharmaceutical manufacturing facility without regulatory findings, highlighting the industry's emphasis on quality-controlled production environments. Growing utilization of prostate-specific membrane antigen imaging and other targeted radiotracers is reinforcing the importance of reliable radiopharmaceutical manufacturing infrastructure capable of supporting expanding clinical demand for advanced molecular imaging procedures.
Isotope Supply Expansion and Workforce Development Strengthen Industry Foundations
The long-term growth of nuclear medicine increasingly depends on robust isotope supply chains and specialized clinical expertise. TMC Group expanded production capacity at its Canadian isotope facility through the commissioning of new production lines dedicated to high-purity enriched stable isotopes such as Yb-176 and Gd-160. This expansion supports research, development, and commercialization activities associated with next-generation radiotheranostic agents. At the same time, the Society of Nuclear Medicine and Molecular Imaging Annual Meeting brought together nearly 8,000 participants and highlighted advancements across theranostics, AI-assisted quantitative imaging, and technologist training initiatives. Industry stakeholders are increasingly prioritizing workforce certification programs and therapy-focused clinical education to support the growing complexity of nuclear medicine procedures. These developments illustrate a broader industry effort to strengthen the infrastructure, talent base, and supply chain capabilities required to support the expanding role of precision nuclear medicine in healthcare delivery.
Nuclear Medicine Market Trends, Growth Drivers, Competitive Landscape, and Future Opportunities
The global Nuclear Medicine market is witnessing increasing investments in innovation, product development, digital transformation, artificial intelligence integration, healthcare infrastructure expansion, and strategic partnerships across developed and emerging economies. Key Companies in the industry include- GE Healthcare, Siemens Healthineers AG, Novartis AG, Curium Pharmaceuticals, Lantheus Holdings, Inc., Cardinal Health, Inc., Bracco Imaging S.p.A., Eckert & Ziegler Group, Jubilant DraxImage Inc., Mallinckrodt plc. The Nuclear Medicine market is expected to remain one of the most closely watched segments in the global healthcare industry, with companies focusing on niche market segments. As healthcare systems across the US, Europe, Asia-Pacific, Latin America, and Middle East & Africa continue to prioritize efficiency, access, and innovation, the Nuclear Medicine industry outlook remains shaped by rising healthcare expenditure, demographic change, digital transformation, and product innovation.
The report provides detailed market analysis including-
- Growth Nuclear Medicine Market size outlook across 3 scenarios- High growth, reference, and Low growth cases
- Market Trends, Drivers, Potential Opportunities, and Challenges faced by Nuclear Medicine companies
- Porter’s Five forces analysis- Bargaining power of buyers and sellers, Threat of Substitutes and new entrants, and Intensity of competitive rivalry
- Detailed SWOT Analysis of global and regional Nuclear Medicine markets
- Competitive analysis including business description, product analysis, and financial profiles
- Key country specific analysis detailing key factors shaping the short-term and long-term outlook
- Recent industry developments and news including mergers, acquisitions, product launches, expansions, and company announcements
Leading companies in Nuclear Medicine industry include- GE Healthcare, Siemens Healthineers AG, Novartis AG, Curium Pharmaceuticals, Lantheus Holdings, Inc., Cardinal Health, Inc., Bracco Imaging S.p.A., Eckert & Ziegler Group, Jubilant DraxImage Inc., Mallinckrodt plc. The Nuclear Medicine market remains moderately to highly fragmented, with competition expected to intensify as companies accelerate investments in innovation, geographic expansion, strategic partnerships, and portfolio diversification through 2034. In developed markets such as the United States, Germany, France, the United Kingdom, and Canada, competition is increasingly centered on innovation, reimbursement positioning, and value-based healthcare solutions. Meanwhile, emerging markets including China, India, Brazil, and countries across the Middle East and Africa continue to present significant opportunities for expansion due to rising healthcare expenditure, growing patient populations, and increasing access to healthcare services.
What to expect in US Nuclear Medicine Markets in 2026 and beyond- Market Size, Share, Growth Rate, and Forecast to 2034
The US healthcare expenditure is forecast to reach $8.2 Trillion in 2034 from $5.5 Trillion in 2026 based on the National Health Expenditure Accounts (NHEA) data. With an aging population, rising chronic disease burden, and increasing migration toward minimally invasive and outpatient care, the Nuclear Medicine market remains one of the strongest-performing segments in the country.
The US Nuclear Medicine Companies are opting new business models, optimized pricing models, industry partnerships, and AI-enabled back end transformations to enhance efficiency and cost management. The US Nuclear Medicine market faces successive waves of challenging trends, with strong opportunities across select segments. The CMS plan to implement Medicaid from 2027 is driving states to build eligibility verification systems throughout 2026. Looking ahead to 2034, we anticipate stronger results underpinned by opportunities exist across Nuclear Medicine industry. On the medical device front, over 7,000 device manufacturers continue to gain from increasing demand from demand for implantable devices, surgical instruments, monitoring equipment, and diagnostic systems.
Canada- Proximity to the US and healthcare similarities to EU5 countries fuel sales of Canadian Nuclear Medicine markets
Canada's strong Nuclear Medicine sales performance is underpinned by an aging population and a well-developed healthcare infrastructure. Steady growth in new brand spending in rural and urban locations fuel the long-term prospects of small and medium-sized enterprises across medical, diagnostic, and therapeutic devices. The Canadian Nuclear Medicine market presents significant opportunities for U.S. exporters of medical devices, with the U.S. being Canada’s largest trading partner for this sector. Potential advantages including specialized materials, advanced manufacturing techniques, and digital technologies support the launch of new products in the country.
Germany Nuclear Medicine Trends and Perspectives to 2034- Financial sustainability, hospital restructuring, demographic pressures, and digitization of care delivery continue to shape the German healthcare industry.
Germany continues to remain the largest Nuclear Medicine market in Europe, driven by over €600 Billion healthcare expenditure, €12 Billion medical device R&D expenditure, statutory health insurance system covering 90% German population, nationwide rollout of the electronic patient record (ePA), and large-volume of Nuclear Medicine population. In particular, Research and development in Germany fuels the commercialization of cutting-edge technologies. Companies across the Germany Nuclear Medicine industry value chain are focusing on both domestic markets and exports. The country is also driving digital adoption with the Hospital Future Act driving hospitals to upgrade their information systems by 2027. Over the forecast period, aging population, rising healthcare costs, and increasing procedural volumes drive the Nuclear Medicine market outlook.
France Market Size, Growth Rate, and Forecast Analysis to 2034- Universal healthcare system, high public healthcare expenditure, and strong government support Nuclear Medicine sales through 2034
France Nuclear Medicine companies are emphasizing on opportunities for rapid, at-scale innovation to boost profitability over the long-term. The country’s National Health Insurance spending target (ONDAM) estimates 3.7% growth in the country’s healthcare expenditure. Over the forecast period, expenditure control measures, chronic disease management initiatives, workforce reforms, and efforts to improve system efficiency drive the long-term prospects.
The biggest 2026 policy frame is the PLFSS 2026. The law sets the Maladie branch spending target at €271.4 billion for 2026 and fixes the ONDAM at €117.5 billion for city care, €112.8 billion for health establishments, and €18.3 billion for elderly-care establishments and services. France’s market is also being pulled by demographics. INSEE estimates that on 1 January 2026 France had 69.1 million inhabitants, with 22% aged 65 or over. INSEE also reported that 2025 births were 645,000 and deaths were 651,000, producing a negative natural balance of about 6,000 for the first time since the end of the Second World War.
UK Nuclear Medicine Market Size, Share, and Growth Projections to 2034- Rapid growth driven by new and existing brands across the industry value chain
Small high-need consumer segments remain key priority of Nuclear Medicine distributors in the UK industry. Continuous launch of new products coupled with high expenditures support the market outlook. The UK Government financing remains the dominant funding source at 81.3% of total healthcare expenditure, or ?280 billion in 2025. According to the ONS, total healthcare spending grew 7.7% nominally and 3.9% in real terms from 2024 to 2025. Similarly, out-of-pocket spending was ?49 billion (14.1%) and voluntary health insurance was ?9.5 billion (2.8%). The market is driven by rapid digital adoption with NHS England’s plan to give more than 500,000 staff access to new AI tools.
China Nuclear Medicine Market Growth Drivers, Revenue Trends, and Forecast- Medical insurance coverage is rapidly expanding over the past few years
China Nuclear Medicine market is undergoing a structural shift from hospital-centric care toward a more integrated system emphasizing primary care, outpatient services, and long-term care. Chinese local players are emerging as a strong pillar of Nuclear Medicine industry, offering opportunities for both competition and partnership. Over the forecast period, new and innovative product launches remain key elements driving market outlook. China's healthcare industry is increasingly centered on expanding healthcare capacity, improving access to advanced treatments, and reducing dependence on imported technologies.
The National Healthcare Security Administration reported that by end-2024, China’s basic medical insurance covered 1.32662 billion people and the coverage rate was 95%. Regional disparities in consumer spending trends continue to become more pronounced in the Chinese Nuclear Medicine industry. Over the forecast period, demand will keep shifting toward geriatrics, chronic disease management, rehabilitation, long-term care, and outpatient care, while pricing pressure will remain intense in drugs and consumables because reimbursement.
India Nuclear Medicine Market Landscape: Current Size and Long-Term Growth Outlook - Increased pricing pressures in US market is encouraging domestic vendors to expand across India
Indian Nuclear Medicine market is witnessing the rapid emergence of an ecosystem that brings together diverse companies across the industry value chain. Further, large-scale healthcare public and private investments and a steady growth in chronic conditions is driving sales of pharmaceuticals and medical devices. Further, non-retail channel is experiencing volume decrease and patients are migrating to the retail. Indian medical device firms are also combining precision engineering with lower labor costs to make world-class diagnostics, robotics, and critical care devices.
Brazil Nuclear Medicine market remains price-driven, with products domestically manufactured and accessibility offering potential opportunities
Healthcare expenditure in Brazil exceeds 10% of GDP, with the country among the highest healthcare spenders in Latin America. ANS reported 53.2 million medical-plan beneficiaries in December 2025, while IBGE projects a steady rise in older-age cohorts, with people aged 60+ already representing about 23% of the population. The price sensitive market access is broad through the public system, private coverage adds a sizeable premium layer, and reimbursement, procurement, and hospital efficiency remain key buying drivers.
Middle East and Africa Nuclear Medicine Industry Trends and Perspectives to 2034
According to the World Bank, the Middle East and North Africa population exceeds 500 million, while Sub-Saharan Africa's population exceeds 1.2 billion, making the broader MEA region one of the fastest-growing healthcare demand centers globally. The GCC countries including Saudi Arabia, United Arab Emirates, Qatar, and Kuwait continue to account for a disproportionately large share of regional healthcare spending. Government-led programs such as Saudi Arabia's Vision 2030 are accelerating investments in hospital infrastructure, private-sector participation, medical technology adoption, and healthcare digitalization. On the other hand, South Africa, Egypt, Nigeria, and Kenya remain key healthcare markets due to their large populations, expanding private healthcare sectors, and growing investments in healthcare delivery systems.
Nuclear Medicine Market Segmentation
By Product Type
Diagnostics
SPECT Radiopharmaceuticals
PET Radiopharmaceuticals
Therapeutics
Alpha Emitters
Beta Emitters
Brachytherapy Isotopes
By Application
Oncology
Cardiology
Neurology
Urology
Thyroid and Endocrine Disorders
Other Applications
By End-Use
Hospitals
Diagnostic and Imaging Centers
Leading Companies in Nuclear Medicine Industry (2026)
GE Healthcare
Siemens Healthineers AG
Novartis AG
Curium Pharmaceuticals
Lantheus Holdings, Inc.
Cardinal Health, Inc.
Bracco Imaging S.p.A.
Eckert & Ziegler Group
Jubilant DraxImage Inc.
Mallinckrodt plc
Countries Included
- North America- US, Canada, Mexico
- Europe- Germany, France, UK, Spain, Italy, Nordics, Others
- Asia Pacific- China, India, Japan, South Korea, Australia, Southeast Asia, Others
- Latin America- Brazil, Argentina, Others
- Middle East and Africa- Saudi Arabia, UAE, Other Middle East, South Africa, Other Africa
- Get Free print authentication across single, multi, and global licenses
- Free Accompanying excel spreadsheet with complete quantitative data
- Free 2-day consulting support from the lead analyst of the team that developed the report
- Gain clear understanding of current market conditions across 20 countries and plan your decisions accordingly
- Understand competitive profiles of the leading 15 companies in the Electrosurgical Generators industry
- Stay ahead of competition through a detailed analysis of recent market developments
- Make trusted decisions building on our 10-year experience in developing reports on Electrosurgical Generators industry
CHAPTER 1- EXECUTIVE SUMMARY
1.1. Market Snapshot: Market Size, CAGR, and Growth Outlook to 2034
1.2. Key Industry Highlights, 2026
1.3. Premium Market Insights
1.3.1. Potential Nuclear Medicine Market Types and Applications
1.3.2. Fastest Growing Countries Over the forecast period
1.4. Market Scope and Segmentation
1.4.1. Key Market Segments
1.4.2. Key Countries and Regions
1.4.3. Top Companies in the Nuclear Medicine Industry
1.5. Macroeconomic and Demographic Outlook
1.5.1. GDP Outlook by Top 20 Countries, 2010- 2040
1.5.2. Population Forecast by Country, 2010- 2040
1.5.3. Inflation Trends in Leading Countries
1.6. Impact of Trade Policies, Regulations, and Sustainability
1.6.1. Trade tariffs and localization requirements
1.6.2. ESG and sustainability pressures
1.6.3. Compliance-driven structural changes in the value chain
CHAPTER 2- RESEARCH METHODOLOGY
2.1. Report Coverage
2.2. Secondary Research
2.3. Primary Research
2.4. Data Triangulation
2.5. Market Modeling and Forecasting
CHAPTER 3- GLOBAL NUCLEAR MEDICINE MARKET TRENDS, GROWTH DRIVERS, CHALLENGES, AND OPPORTUNITIES THROUGH 2034
3.1. An Introduction to Global Nuclear Medicine Markets in 2026
3.2. Global Historic and Forecast Nuclear Medicine Market Size Outlook, USD Million, 2021- 2034
3.3. Annual Market Size Growth Rate (Y-o-Y), %, 2021-2034
3.4. Market Dynamics
3.4.1. Key Nuclear Medicine Market Driving Forces and Their Impact on Market Outlook
3.4.2. Short and Long-Term Trends and Insights Shaping the Future
3.4.3. Potential Nuclear Medicine Market Opportunities for Industry Stakeholders
3.4.4. Potential Challenges across Nuclear Medicine Value Chain
CHAPTER 4- NUCLEAR MEDICINE MARKET COMPETITIVE LANDSCAPE, STRATEGIC ANALYSIS, AND VALUE CHAIN ASSESSMENT
4.1. Porter’s Five Forces Analysis
4.1.1. Bargaining Power of Buyers
4.1.2. Bargaining Power of Suppliers
4.1.3. Threat of Substitutes
4.1.4. Threat of New Entrants
4.1.5. Intensity of Competitive Rivalry
4.1.6. Market Attractiveness Analysis by Segment
4.1.7. Market Attractiveness Analysis by Region
4.2. Competitive Landscape
4.2.1 Market Share Analysis of Leading Nuclear Medicine Companies
4.2.2 Recent Strategic Developments
4.2.3 Mergers, Acquisitions, and Partnerships
4.2.4 Product Launches and Innovation Trends
4.2.5 Key Success Factors
4.3. Value Chain Analysis
4.3.1. Key Value Chain Segments
4.3.2. Dominant players by value-chain stage
4.4. SWOT Analysis
4.4.1. Key Strengths and Opportunities
4.4.2. Major Weaknesses and Threats
4.5 Technology Roadmap
4.6 Regulatory and Reimbursement Landscape
CHAPTER 5- NUCLEAR MEDICINE MARKET OUTLOOK BY SEGMENTS
5.1. Market Size Outlook by Type, USD Million, 2021- 2025 and 2026-2034
5.2. Market Size Outlook by Application, USD Million, 2021- 2025 and 2026-2034
5.3. Market Size Outlook by Country, USD Million, 2021- 2025 and 2026-2034
By Product Type
Diagnostics
SPECT Radiopharmaceuticals
PET Radiopharmaceuticals
Therapeutics
Alpha Emitters
Beta Emitters
Brachytherapy Isotopes
By Application
Oncology
Cardiology
Neurology
Urology
Thyroid and Endocrine Disorders
Other Applications
By End-Use
Hospitals
Diagnostic and Imaging Centers
CHAPTER 6- SCENARIO ANALYSIS AND OUTLOOK
6.1. Base Case Scenario
6.1.1. Definitions and Insights
6.1.2. Market Size Outlook to 2034
6.2. Low Growth Case Scenario
6.2.1. Definitions and Insights
6.2.2. Market Size Outlook to 2034
6.3. High Growth Case Scenario
6.3.1. Definitions and Insights
6.3.2. Market Size Outlook to 2034
CHAPTER 7- NORTH AMERICA NUCLEAR MEDICINE MARKET SIZE ANALYSIS AND OUTLOOK
7.1. North America Nuclear Medicine Market Overview, 2026
7.2. Leading Companies Operating in North America
7.3. Key Industry Statistics, 2026
7.4. North America Nuclear Medicine Market Trends and Growth Opportunities to 2034
7.5. North America Nuclear Medicine Market Size Outlook by Type
7.6. North America Nuclear Medicine Market Size Outlook by Application
7.7. North America Nuclear Medicine Market Size Outlook by Country
7.8. United States
7.8.1. Key Statistics
7.8.2. The US Nuclear Medicine Market Size Outlook, 2021- 2034
7.8.3. Key Market Drivers and Industry Developments in the US Nuclear Medicine Companies
7.9. Canada
7.9.1. Key Statistics
7.9.2. Canada Nuclear Medicine Market Size Outlook, 2021- 2034
7.9.3. Key Market Drivers and Industry Developments in Canada Nuclear Medicine Companies
7.10. Mexico
7.10.1. Key Statistics
7.10.2. Mexico Nuclear Medicine Market Size Outlook, 2021- 2034
7.10.3. Key Market Drivers and Industry Developments in Mexico Nuclear Medicine Companies
CHAPTER 8- EUROPE NUCLEAR MEDICINE MARKET SIZE ANALYSIS AND OUTLOOK
8.1. Europe Nuclear Medicine Market Overview, 2026
8.2. Leading Companies Operating in Europe
8.3. Key Industry Statistics, 2026
8.4. Europe Nuclear Medicine Market Trends and Growth Opportunities to 2034
8.5. Europe Nuclear Medicine Market Size Outlook by Type
8.6. Europe Nuclear Medicine Market Size Outlook by Application
8.7. Europe Nuclear Medicine Market Size Outlook by Country
8.8. Germany
8.8.1. Key Statistics
8.8.2. Germany Nuclear Medicine Market Size Outlook, 2021- 2034
8.8.3. Key Market Drivers and Industry Developments in Germany Nuclear Medicine Companies
8.9. France
8.9.1. Key Statistics
8.9.2. France Nuclear Medicine Market Size Outlook, 2021- 2034
8.9.3. Key Market Drivers and Industry Developments in France Nuclear Medicine Companies
8.10. United Kingdom
8.10.1. Key Statistics
8.10.2. United Kingdom Nuclear Medicine Market Size Outlook, 2021- 2034
8.10.3. Key Market Drivers and Industry Developments in the UK Nuclear Medicine Companies
8.11. Spain
8.11.1. Key Statistics
8.11.2. Spain Nuclear Medicine Market Size Outlook, 2021- 2034
8.11.3. Key Market Drivers and Industry Developments in Spain Nuclear Medicine Companies
8.12. Italy
8.12.1. Key Statistics
8.12.2. Italy Nuclear Medicine Market Size Outlook, 2021- 2034
8.12.3. Key Market Drivers and Industry Developments in Italy Nuclear Medicine Companies
8.13. Rest of Europe
8.13.1. Key Statistics
8.13.2. Rest of Europe Nuclear Medicine Market Size Outlook, 2021- 2034
8.13.3. Key Market Drivers and Industry Developments in Rest of Europe Nuclear Medicine Companies
CHAPTER 9- ASIA PACIFIC NUCLEAR MEDICINE MARKET SIZE ANALYSIS AND OUTLOOK
9.1. Asia Pacific Nuclear Medicine Market Overview, 2026
9.2. Leading Companies Operating in Asia Pacific
9.3. Key Industry Statistics, 2026
9.4. Asia Pacific Nuclear Medicine Market Trends and Growth Opportunities to 2034
9.5. Asia Pacific Nuclear Medicine Market Size Outlook by Type
9.6. Asia Pacific Nuclear Medicine Market Size Outlook by Application
9.7. Asia Pacific Nuclear Medicine Market Size Outlook by Country
9.8. China
9.8.1. Key Statistics
9.8.2. China Nuclear Medicine Market Size Outlook, 2021- 2034
9.8.3. Key Market Drivers and Industry Developments in China Nuclear Medicine Companies
9.9. Japan
9.9.1. Key Statistics
9.9.2. Japan Nuclear Medicine Market Size Outlook, 2021- 2034
9.9.3. Key Market Drivers and Industry Developments in Japan Nuclear Medicine Companies
9.10. India
9.10.1. Key Statistics
9.10.2. India Nuclear Medicine Market Size Outlook, 2021- 2034
9.10.3. Key Market Drivers and Industry Developments in India Nuclear Medicine Companies
9.11. South Korea
9.11.1. Key Statistics
9.11.2. South Korea Nuclear Medicine Market Size Outlook, 2021- 2034
9.11.3. Key Market Drivers and Industry Developments in South Korea Nuclear Medicine Companies
9.12. Australia
9.12.1. Key Statistics
9.12.2. Australia Nuclear Medicine Market Size Outlook, 2021- 2034
9.12.3. Key Market Drivers and Industry Developments in Australia Nuclear Medicine Companies
9.13. Southeast Asia
9.13.1. Key Statistics
9.13.2. Southeast Asia Nuclear Medicine Market Size Outlook, 2021- 2034
9.13.3. Key Market Drivers and Industry Developments in Southeast Asia Nuclear Medicine Companies
CHAPTER 10- SOUTH AND CENTRAL AMERICA NUCLEAR MEDICINE MARKET SIZE ANALYSIS AND OUTLOOK
10.1. South and Central America Nuclear Medicine Market Overview, 2026
10.2. Leading Companies Operating in South and Central America
10.3. Key Industry Statistics, 2026
10.4. South and Central America Nuclear Medicine Market Trends and Growth Opportunities to 2034
10.5. South and Central America Nuclear Medicine Market Size Outlook by Type
10.6. South and Central America Nuclear Medicine Market Size Outlook by Application
10.7. South and Central America Nuclear Medicine Market Size Outlook by Country
10.8. Brazil
10.8.1. Key Statistics
10.8.2. Brazil Nuclear Medicine Market Size Outlook, 2021- 2034
10.8.3. Key Market Drivers and Industry Developments in Brazil Nuclear Medicine Companies
10.9. Argentina
10.9.1. Key Statistics
10.9.2. Argentina Nuclear Medicine Market Size Outlook, 2021- 2034
10.9.3. Key Market Drivers and Industry Developments in Argentina Nuclear Medicine Companies
10.10. Rest of Latin America
10.10.1. Key Statistics
10.10.2. Rest of Latin America Nuclear Medicine Market Size Outlook, 2021- 2034
10.10.3. Key Market Drivers and Industry Developments in Rest of Latin America Nuclear Medicine Companies
CHAPTER 11- MIDDLE EAST AND AFRICA NUCLEAR MEDICINE MARKET SIZE ANALYSIS AND OUTLOOK
11.1. Middle East and Africa Nuclear Medicine Market Overview, 2026
11.2. Leading Companies Operating in Middle East and Africa
11.3. Key Industry Statistics, 2026
11.4. Middle East and Africa Nuclear Medicine Market Trends and Growth Opportunities to 2034
11.5. Middle East and Africa Nuclear Medicine Market Size Outlook by Type
11.6. Middle East and Africa Nuclear Medicine Market Size Outlook by Application
11.7. Middle East and Africa Nuclear Medicine Market Size Outlook by Country
11.8. Saudi Arabia
11.8.1. Key Statistics
11.8.2. Saudi Arabia Nuclear Medicine Market Size Outlook, 2021- 2034
11.8.3. Key Market Drivers and Industry Developments in Saudi Arabia Nuclear Medicine Companies
11.9. United Arab Emirates
11.9.1. Key Statistics
11.9.2. The UAE Nuclear Medicine Market Size Outlook, 2021- 2034
11.9.3. Key Market Drivers and Industry Developments in the UAE Nuclear Medicine Companies
11.10. Africa
11.10.1. Key Statistics
11.10.2. Africa Nuclear Medicine Market Size Outlook, 2021- 2034
11.10.3. Key Market Drivers and Industry Developments in Africa Nuclear Medicine Companies
CHAPTER 12- COMPANY PROFILES
12.1. Top Companies in Nuclear Medicine Industry
GE Healthcare
Siemens Healthineers AG
Novartis AG
Curium Pharmaceuticals
Lantheus Holdings, Inc.
Cardinal Health, Inc.
Bracco Imaging S.p.A.
Eckert & Ziegler Group
Jubilant DraxImage Inc.
Mallinckrodt plc
12.2. Business Description
12.3. SWOT Profiles
12.4. Products and Services
CHAPTER 13- APPENDIX
Glossary of Terms
Research Methodology & Data Sources
Conclusion & Strategic Recommendations
1.1. Market Snapshot: Market Size, CAGR, and Growth Outlook to 2034
1.2. Key Industry Highlights, 2026
1.3. Premium Market Insights
1.3.1. Potential Nuclear Medicine Market Types and Applications
1.3.2. Fastest Growing Countries Over the forecast period
1.4. Market Scope and Segmentation
1.4.1. Key Market Segments
1.4.2. Key Countries and Regions
1.4.3. Top Companies in the Nuclear Medicine Industry
1.5. Macroeconomic and Demographic Outlook
1.5.1. GDP Outlook by Top 20 Countries, 2010- 2040
1.5.2. Population Forecast by Country, 2010- 2040
1.5.3. Inflation Trends in Leading Countries
1.6. Impact of Trade Policies, Regulations, and Sustainability
1.6.1. Trade tariffs and localization requirements
1.6.2. ESG and sustainability pressures
1.6.3. Compliance-driven structural changes in the value chain
CHAPTER 2- RESEARCH METHODOLOGY
2.1. Report Coverage
2.2. Secondary Research
2.3. Primary Research
2.4. Data Triangulation
2.5. Market Modeling and Forecasting
CHAPTER 3- GLOBAL NUCLEAR MEDICINE MARKET TRENDS, GROWTH DRIVERS, CHALLENGES, AND OPPORTUNITIES THROUGH 2034
3.1. An Introduction to Global Nuclear Medicine Markets in 2026
3.2. Global Historic and Forecast Nuclear Medicine Market Size Outlook, USD Million, 2021- 2034
3.3. Annual Market Size Growth Rate (Y-o-Y), %, 2021-2034
3.4. Market Dynamics
3.4.1. Key Nuclear Medicine Market Driving Forces and Their Impact on Market Outlook
3.4.2. Short and Long-Term Trends and Insights Shaping the Future
3.4.3. Potential Nuclear Medicine Market Opportunities for Industry Stakeholders
3.4.4. Potential Challenges across Nuclear Medicine Value Chain
CHAPTER 4- NUCLEAR MEDICINE MARKET COMPETITIVE LANDSCAPE, STRATEGIC ANALYSIS, AND VALUE CHAIN ASSESSMENT
4.1. Porter’s Five Forces Analysis
4.1.1. Bargaining Power of Buyers
4.1.2. Bargaining Power of Suppliers
4.1.3. Threat of Substitutes
4.1.4. Threat of New Entrants
4.1.5. Intensity of Competitive Rivalry
4.1.6. Market Attractiveness Analysis by Segment
4.1.7. Market Attractiveness Analysis by Region
4.2. Competitive Landscape
4.2.1 Market Share Analysis of Leading Nuclear Medicine Companies
4.2.2 Recent Strategic Developments
4.2.3 Mergers, Acquisitions, and Partnerships
4.2.4 Product Launches and Innovation Trends
4.2.5 Key Success Factors
4.3. Value Chain Analysis
4.3.1. Key Value Chain Segments
4.3.2. Dominant players by value-chain stage
4.4. SWOT Analysis
4.4.1. Key Strengths and Opportunities
4.4.2. Major Weaknesses and Threats
4.5 Technology Roadmap
4.6 Regulatory and Reimbursement Landscape
CHAPTER 5- NUCLEAR MEDICINE MARKET OUTLOOK BY SEGMENTS
5.1. Market Size Outlook by Type, USD Million, 2021- 2025 and 2026-2034
5.2. Market Size Outlook by Application, USD Million, 2021- 2025 and 2026-2034
5.3. Market Size Outlook by Country, USD Million, 2021- 2025 and 2026-2034
By Product Type
Diagnostics
SPECT Radiopharmaceuticals
PET Radiopharmaceuticals
Therapeutics
Alpha Emitters
Beta Emitters
Brachytherapy Isotopes
By Application
Oncology
Cardiology
Neurology
Urology
Thyroid and Endocrine Disorders
Other Applications
By End-Use
Hospitals
Diagnostic and Imaging Centers
CHAPTER 6- SCENARIO ANALYSIS AND OUTLOOK
6.1. Base Case Scenario
6.1.1. Definitions and Insights
6.1.2. Market Size Outlook to 2034
6.2. Low Growth Case Scenario
6.2.1. Definitions and Insights
6.2.2. Market Size Outlook to 2034
6.3. High Growth Case Scenario
6.3.1. Definitions and Insights
6.3.2. Market Size Outlook to 2034
CHAPTER 7- NORTH AMERICA NUCLEAR MEDICINE MARKET SIZE ANALYSIS AND OUTLOOK
7.1. North America Nuclear Medicine Market Overview, 2026
7.2. Leading Companies Operating in North America
7.3. Key Industry Statistics, 2026
7.4. North America Nuclear Medicine Market Trends and Growth Opportunities to 2034
7.5. North America Nuclear Medicine Market Size Outlook by Type
7.6. North America Nuclear Medicine Market Size Outlook by Application
7.7. North America Nuclear Medicine Market Size Outlook by Country
7.8. United States
7.8.1. Key Statistics
7.8.2. The US Nuclear Medicine Market Size Outlook, 2021- 2034
7.8.3. Key Market Drivers and Industry Developments in the US Nuclear Medicine Companies
7.9. Canada
7.9.1. Key Statistics
7.9.2. Canada Nuclear Medicine Market Size Outlook, 2021- 2034
7.9.3. Key Market Drivers and Industry Developments in Canada Nuclear Medicine Companies
7.10. Mexico
7.10.1. Key Statistics
7.10.2. Mexico Nuclear Medicine Market Size Outlook, 2021- 2034
7.10.3. Key Market Drivers and Industry Developments in Mexico Nuclear Medicine Companies
CHAPTER 8- EUROPE NUCLEAR MEDICINE MARKET SIZE ANALYSIS AND OUTLOOK
8.1. Europe Nuclear Medicine Market Overview, 2026
8.2. Leading Companies Operating in Europe
8.3. Key Industry Statistics, 2026
8.4. Europe Nuclear Medicine Market Trends and Growth Opportunities to 2034
8.5. Europe Nuclear Medicine Market Size Outlook by Type
8.6. Europe Nuclear Medicine Market Size Outlook by Application
8.7. Europe Nuclear Medicine Market Size Outlook by Country
8.8. Germany
8.8.1. Key Statistics
8.8.2. Germany Nuclear Medicine Market Size Outlook, 2021- 2034
8.8.3. Key Market Drivers and Industry Developments in Germany Nuclear Medicine Companies
8.9. France
8.9.1. Key Statistics
8.9.2. France Nuclear Medicine Market Size Outlook, 2021- 2034
8.9.3. Key Market Drivers and Industry Developments in France Nuclear Medicine Companies
8.10. United Kingdom
8.10.1. Key Statistics
8.10.2. United Kingdom Nuclear Medicine Market Size Outlook, 2021- 2034
8.10.3. Key Market Drivers and Industry Developments in the UK Nuclear Medicine Companies
8.11. Spain
8.11.1. Key Statistics
8.11.2. Spain Nuclear Medicine Market Size Outlook, 2021- 2034
8.11.3. Key Market Drivers and Industry Developments in Spain Nuclear Medicine Companies
8.12. Italy
8.12.1. Key Statistics
8.12.2. Italy Nuclear Medicine Market Size Outlook, 2021- 2034
8.12.3. Key Market Drivers and Industry Developments in Italy Nuclear Medicine Companies
8.13. Rest of Europe
8.13.1. Key Statistics
8.13.2. Rest of Europe Nuclear Medicine Market Size Outlook, 2021- 2034
8.13.3. Key Market Drivers and Industry Developments in Rest of Europe Nuclear Medicine Companies
CHAPTER 9- ASIA PACIFIC NUCLEAR MEDICINE MARKET SIZE ANALYSIS AND OUTLOOK
9.1. Asia Pacific Nuclear Medicine Market Overview, 2026
9.2. Leading Companies Operating in Asia Pacific
9.3. Key Industry Statistics, 2026
9.4. Asia Pacific Nuclear Medicine Market Trends and Growth Opportunities to 2034
9.5. Asia Pacific Nuclear Medicine Market Size Outlook by Type
9.6. Asia Pacific Nuclear Medicine Market Size Outlook by Application
9.7. Asia Pacific Nuclear Medicine Market Size Outlook by Country
9.8. China
9.8.1. Key Statistics
9.8.2. China Nuclear Medicine Market Size Outlook, 2021- 2034
9.8.3. Key Market Drivers and Industry Developments in China Nuclear Medicine Companies
9.9. Japan
9.9.1. Key Statistics
9.9.2. Japan Nuclear Medicine Market Size Outlook, 2021- 2034
9.9.3. Key Market Drivers and Industry Developments in Japan Nuclear Medicine Companies
9.10. India
9.10.1. Key Statistics
9.10.2. India Nuclear Medicine Market Size Outlook, 2021- 2034
9.10.3. Key Market Drivers and Industry Developments in India Nuclear Medicine Companies
9.11. South Korea
9.11.1. Key Statistics
9.11.2. South Korea Nuclear Medicine Market Size Outlook, 2021- 2034
9.11.3. Key Market Drivers and Industry Developments in South Korea Nuclear Medicine Companies
9.12. Australia
9.12.1. Key Statistics
9.12.2. Australia Nuclear Medicine Market Size Outlook, 2021- 2034
9.12.3. Key Market Drivers and Industry Developments in Australia Nuclear Medicine Companies
9.13. Southeast Asia
9.13.1. Key Statistics
9.13.2. Southeast Asia Nuclear Medicine Market Size Outlook, 2021- 2034
9.13.3. Key Market Drivers and Industry Developments in Southeast Asia Nuclear Medicine Companies
CHAPTER 10- SOUTH AND CENTRAL AMERICA NUCLEAR MEDICINE MARKET SIZE ANALYSIS AND OUTLOOK
10.1. South and Central America Nuclear Medicine Market Overview, 2026
10.2. Leading Companies Operating in South and Central America
10.3. Key Industry Statistics, 2026
10.4. South and Central America Nuclear Medicine Market Trends and Growth Opportunities to 2034
10.5. South and Central America Nuclear Medicine Market Size Outlook by Type
10.6. South and Central America Nuclear Medicine Market Size Outlook by Application
10.7. South and Central America Nuclear Medicine Market Size Outlook by Country
10.8. Brazil
10.8.1. Key Statistics
10.8.2. Brazil Nuclear Medicine Market Size Outlook, 2021- 2034
10.8.3. Key Market Drivers and Industry Developments in Brazil Nuclear Medicine Companies
10.9. Argentina
10.9.1. Key Statistics
10.9.2. Argentina Nuclear Medicine Market Size Outlook, 2021- 2034
10.9.3. Key Market Drivers and Industry Developments in Argentina Nuclear Medicine Companies
10.10. Rest of Latin America
10.10.1. Key Statistics
10.10.2. Rest of Latin America Nuclear Medicine Market Size Outlook, 2021- 2034
10.10.3. Key Market Drivers and Industry Developments in Rest of Latin America Nuclear Medicine Companies
CHAPTER 11- MIDDLE EAST AND AFRICA NUCLEAR MEDICINE MARKET SIZE ANALYSIS AND OUTLOOK
11.1. Middle East and Africa Nuclear Medicine Market Overview, 2026
11.2. Leading Companies Operating in Middle East and Africa
11.3. Key Industry Statistics, 2026
11.4. Middle East and Africa Nuclear Medicine Market Trends and Growth Opportunities to 2034
11.5. Middle East and Africa Nuclear Medicine Market Size Outlook by Type
11.6. Middle East and Africa Nuclear Medicine Market Size Outlook by Application
11.7. Middle East and Africa Nuclear Medicine Market Size Outlook by Country
11.8. Saudi Arabia
11.8.1. Key Statistics
11.8.2. Saudi Arabia Nuclear Medicine Market Size Outlook, 2021- 2034
11.8.3. Key Market Drivers and Industry Developments in Saudi Arabia Nuclear Medicine Companies
11.9. United Arab Emirates
11.9.1. Key Statistics
11.9.2. The UAE Nuclear Medicine Market Size Outlook, 2021- 2034
11.9.3. Key Market Drivers and Industry Developments in the UAE Nuclear Medicine Companies
11.10. Africa
11.10.1. Key Statistics
11.10.2. Africa Nuclear Medicine Market Size Outlook, 2021- 2034
11.10.3. Key Market Drivers and Industry Developments in Africa Nuclear Medicine Companies
CHAPTER 12- COMPANY PROFILES
12.1. Top Companies in Nuclear Medicine Industry
GE Healthcare
Siemens Healthineers AG
Novartis AG
Curium Pharmaceuticals
Lantheus Holdings, Inc.
Cardinal Health, Inc.
Bracco Imaging S.p.A.
Eckert & Ziegler Group
Jubilant DraxImage Inc.
Mallinckrodt plc
12.2. Business Description
12.3. SWOT Profiles
12.4. Products and Services
CHAPTER 13- APPENDIX
Glossary of Terms
Research Methodology & Data Sources
Conclusion & Strategic Recommendations
